Table 1 Characterization of MNPs, Drug loading and Magneto-liposomal formulations.
From: Multifunctional Nanotherapeutics for the Treatment of neuroAIDS in Drug Abusers
Formulation type | Drug loading (%age) | MNP encapsulation efficiency | Hydrodynamic Size (nm) | Zeta Potential (mV) |
|---|---|---|---|---|
MNP | — | — | 18 ± 2.0 | −10 ± 2.5 |
MNP + Tenofovir (1st Layer) | 35 ± 3.5% | — | 18.5 ± 3.5 | 18.5 ± 3.5 |
MNP + Tenofovir (2nd Layer) | 28 ± 3.5% | — | 18.5 ± 1.5 | 18.0 ± 2.0 |
MNP + Nelfinavir | 25 ± 2.0% | — | 18.5 ± 2.0 | 16.5 ± 4.5 |
Blank Liposome | — | — | 340 ± 12.5 | 7.8 ± 1.5 |
Liposome + unloaded MNP | — | 20 ± 4.0% | 360 ± 14.0 | 7.8 ± 2.5 |
Liposome + LRAs | — | 18.0 ± 4.0% | 345 ± 10.5 | 8.5 ± 2.2 |
Liposome + Drug loaded MNP | — | 16.5 ± 3.5% | 380 ± 12.8 | 8.3 ± 2.9 |
Final NF (Liposome + MNPs + Drugs) | — | 18.0 ± 4.0% | 410.0 ± 15.0 | 8.2 ± 2.5 |
